JC

James Campbell

Prescient Therapeutics Limited | Non-Executive Director, Non-Executive Chairman
Dr Campbell has more than 25 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple Australian and international biotechnology companies. In 2011 ChemGenex was sold to Cephalon for $230M. Dr Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with capital raising and partnering negotiations. He is a Member of the Risk Committee.

Company and Roles

Company
Title
Tenure
Since
PTX
PTX
Prescient Therapeutics Limited
  • Non-Executive Director
  • Non-Executive Chairman
11yrs, 7mthNov 2014

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
PTX
PTX
Prescient Therapeutics Limited
18/11/25618,365972,0005,257,573N/A
PAB
PAB
22/10/2512,947,115194,0080N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
PTX
PTX
Prescient Therapeutics Limited
18/11/25
Issued
5,257,573$0.048$252,363Issue of options
PAB
PAB
22/10/25
Issued
10,701,795$0.015$160,526Issue of securities
PAB
PAB
30/09/25
Expiry
23,389,950$0.002$46,779Options expired
PAB
PAB
28/08/25
Issued
16,296,678$0.002$32,593Rights issue
PAB
PAB
28/08/25
Issued
1,408,125$0.002$2,816Rights issue